Transdermal Continuous Oxygen Therapy for Diabetic Foot Ulcers

Diabetic Foot Ulcers Clinical Trial

Official title:

A Prospective, Randomized Blinded Multicenter, Parallel Study Comparing Transdermal, Continuous Oxygen Delivery to Moist Wound Therapy (MWT) in the Treatment of Diabetic Foot Ulcers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01291160
• Other study ID #: EPF-409
• Status: Completed
• Phase: Phase 2/Phase 3
• First received: February 4, 2011
• Last updated: April 11, 2014
• Start date: October 2009
• Est. completion date: February 2013

Study information

• Verified date: April 2014
• Source: Ogenix Corporation
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This is a multicenter, prospective, parallel, double-blinded, validation study of up to 12 weeks duration to evaluate the safety and effectiveness of EPIFLO for the treatment of Diabetic Foot Ulcer. The primary objectives of this study are: 1) to evaluate the effectiveness of EPIFLO in combination with standard wound therapy on wound healing as compared to standard wound therapy alone; and 2) Screening for potential safety issues.

Diabetic subjects with a Diabetic Foot Ulcer present for a minimum of 30 days will be enrolled. All subjects enrolled in the study will receive a standard wound therapy regimen consisting of, wound cleansing, moist wound care, off-loading and as appropriate, aggressive debridement. Subjects will be randomized to either the Treatment arm or the Control arm. Subjects will be assessed weekly for signs of wound healing during the 12-week Treatment Period, once two weeks after wound closure and once at the end of 12-week durability Period.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 130
• Est. completion date: February 2013
• Est. primary completion date: February 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 20 Years to 90 Years

Eligibility

Inclusion Criteria:

• Male and female patients 20-90 years of age with type 1 or type 2 diabetes mellitus with non-healing, full-thickness, University of Texas Classification of Diabetic Foot Ulcers Class IA diabetic foot ulcers of at least 4 weeks duration, but not greater than 52 weeks, measuring 1 -10 cm2 in area (Area = length x width) 50% at least from 65+ age group

• Any diabetic foot ulcer at or below the malleoli

• Patients with partial amputation up to & including a TMA

• Subjects; between 20-90 years of age with a diabetic foot ulcer; 50% at least from 65+ age group

• Subjects must have had the wound open for at least 4 weeks from day one on screening visit.

• Subjects wound must be =1 cm2 in size at screening visit, but not greater than 10 cm2.

• Subject's ABI should be = 0.7 on the study limb or transcutaneous partial pressure oxygen (TcpO2) >40mmHg; or a toe pressure =40mmHg; or a Doppler waveform consistent with adequate flow in the foot(biphasic or triphasic waveforms) at screening

• No active malignancy except non-melanoma skin cancer

• Subject and/or caregiver must be willing and able to learn and perform the duties of dressing changes, and demonstrate the ability to do so.

• If patient has had a history of alcohol or substance abuse within 6 months prior to base line period, should provide proof of treatment.

Exclusion Criteria:

• Wounds of duration >52 weeks

• Evidence of gangrene on any part of affected limb;

• Subjects with active Charcot's foot on the study limb;

• Subjects scheduled to undergo vascular surgery, angioplasty or thrombolysis;

• Subjects with infected target ulcers, accompanied by cellulitis, known or suspected osteomyelitis, or other clinical evidence of infection;

• Index ulcer has exposed tendons, ligaments, muscle, or bone.

• ulcers present in between toes

• Target limb is infected at beginning of study

• Must never have had malignancy on study limb

• Oral, or IV antibiotic/antimicrobial agents or medications have been used within 2 days (48 hours) of baseline.

• Patients with steroids >7mg dosage are excluded

• Subject has received growth factor therapy (e.g., autologous platelet-rich plasma gel, becaplermin, bilayered cell therapy, dermal substitute, extracellular matrix) within two weeks of screening date.

• Subject may not be pregnant at the time of treatment.

• Subjects with ulcer that has a total Surface Area of greater than 10 cm2 at Screening Visit as measured by a member of the study staff;

• Subject is undergoing renal dialysis, has known immune insufficiency, other than Diabetes Mellitus

• Ulcers which decrease in area by >30% during the screening 1-week run-in period

• History of peripheral vascular repair within the 30 days of baseline.

• Subject is currently receiving or has received radiation or chemotherapy within 3 months of randomization.

• No known "patient-reported" alcohol or substance abuse within three months prior to baseline.

• Subject currently enrolled or participated within 30 days of baseline in another investigational device, drug or biological trial.

• Subject allergic to a broad spectrum of primary & secondary dressing materials,including occlusive dressings and the adhesives on such dressings.

• Subject with Chopart amputation

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetic Foot
• Diabetic Foot Ulcers
• Foot Ulcer
• Ulcer

Intervention

Device:
• Epiflo
During the Treatment Period, subjects will be administered EPIFLO (either working units or sham units per randomization schedule) in conjunction with standard wound therapy regimen consisting of aggressive debridement, wound cleansing, wound dressing, for a period of 12 weeks, or until the wound completely closes, whichever event occurs first.

Other:
• Moist Wound Therapy
During the Treatment Period, subjects will be administered EPIFLO (either working units or sham units per randomization schedule) in conjunction with standard wound therapy regimen consisting of aggressive debridement, wound cleansing, wound dressing, for a period of 12 weeks, or until the wound completely closes, whichever event occurs first.

Locations

Country	Name	City	State
United States	Boston Medical Center	Boston	Massachusetts
United States	Dean Vayser, DPM	Encinitas	California
United States	California School of Podiatric Medicine	Fresno	California
United States	Ohio College of Podiatric Medicine	Independence	Ohio
United States	UF College of Medicine-Jacksonville	Jacksonville	Florida
United States	Bruce W. Carter Dept. of Veterans Affairs Medical Center, Miami VA Health Care System	Miami	Florida
United States	Carl T. Hayden VA Medical Center	Phoenix	Arizona
United States	The Diabetic Foot	San Marcos,	California
United States	Tacoma Diabetic Foot Center	Tacoma	Washington
United States	Ocean County Foot & Ankle Surgical Associates	Toms River,	New Jersey
United States	Southern AZ VA Health Care System	Tucson	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Ogenix Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of 100% Wound Closure		before or at week 12	No